Table 2.

Competing risk analysis; associations with breast and ovarian cancer risk for BRCA1 mutation carriers in the combined stage 1 and 2 samples

SNP	Genotype	Unaffected (%)	Breast cancer (%)	Ovarian cancer (%)	Ovarian cancer			Breast cancer
					HR	95% CI	Pa	HR	95% CI	Pa
rs8170	GG	2,306 (68.4)	2,631 (63.4)	584 (69.3)	1.00			1.00
	GA	973 (28.9)	1,360 (32.8)	238 (28.2)	1.10	0.92–1.31		1.27	1.17–1.39
	AA	91 (2.7)	159 (3.8)	21 (2.5)	1.06	0.68–1.66		1.58	1.27–1.97
	Per allele				1.07	0.93–1.24	0.33	1.27	1.18–1.36	1.5 × 10−10
rs4808611	GG	2,353 (70.0)	2,696 (65.1)	593 (70.7)	1.00			1.00
	GA	923 (27.5)	1,307 (31.5)	229 (27.3)	1.14	0.96–1.36		1.29	1.18–1.41
	AA	86 (2.6)	141 (3.4)	17 (2.0)	0.99	0.58–1.69		1.54	1.22–1.94
	Per allele				1.10	0.94–1.27	0.34	1.27	1.18–1.37	1.6 × 10−10
rs8100241	GG	793 (23.6)	1,100 (26.5)	188 (22.4)	1.00			1.00
	GA	1,676 (49.8)	2,118 (51.0)	428 (50.9)	1.01	0.83–1.23		0.89	0.81–0.98
	AA	899 (26.7)	933 (22.5)	225 (26.8)	0.89	0.71–1.11		0.70	0.62–0.78
	Per allele				0.94	0.84–1.05	0.28	0.84	0.79–0.88	1.6 × 10−10
rs2363956	AA	793 (23.6)	1,100 (26.5)	188 (22.3)	1.00			1.00
	AC	1,678 (49.8)	2,116 (51.0)	429 (51.0)	1.01	0.83–1.23		0.89	0.80–0.97
	CC	896 (26.6)	934 (22.5)	225 (26.7)	0.89	0.71–1.12		0.70	0.63–0.78
	Per allele				0.94	0.85–1.05	0.30	0.84	0.79–0.88	2.4 × 10−10
rs3745185	GG	1,051 (31.2)	1,423 (34.3)	245 (29.1)	1.00			1.00
	GA	1,675 (49.7)	2,048 (49.3)	437 (51.8)	1.03	0.85–1.23		0.86	0.79–0.94
	AA	643 (19.1)	681 (16.4)	161 (19.1)	0.92	0.73–1.15		0.73	0.65–0.82
	Per allele				0.97	0.86–1.08	0.54	0.86	0.81–0.91	7.1 × 10−8

^aRobust Wald statistic.